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EDITORIAL Open Access
How could we enhance translation of
sepsis immunology to inform
immunomodulation trials in sepsis?
M. Shankar-Hari1,2,3,4
See related research by Antonakos et al., https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1625-1.
Abstract
Sepsis results in complex alterations to the immune
system. Our understanding of how these alterations
in immune responses could help characterize
extreme immune phenotypes, identify biomarkers
with the ability to stratify patients for therapeutic
interventions, surrogates in the causal pathway of
clinical end-points, and treatable traits are still
rudimentary. A methodologically rigorous,
consensus-based approach should enrich sepsis
immune subpopulations to increase the probability
of successful trials.
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Main Text
Sepsis represents life-threatening organ dysfunction
caused by a dysregulated host response to infection [1],
which potentially affects every organ system. Suscepti-
bility to damage, repair, and residual sequelae varies
markedly between both individuals and organs [2], as
do the risk for and outcomes from sepsis, which repre-
sent heterogeneity [3]. Studying the temporal effects of
sepsis on the immune system is challenging as numer-
ous abnormalities differ between sepsis patients and
within the same patient over time [4]. Furthermore, the
time between onset of infection to clinical presentation
varies considerably, influenced by patient characteris-
tics, infection site, pathogen virulence, and access to
healthcare. While novel interventions are frequently
discovered and tested, numerous trials are statistically
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negative [3]. While these interventions may indeed be
completely ineffective, it is perhaps more plausible that
a benefitting subset is diluted by the overall lack of sig-
nal or even harm [5]. Thus, reassessing our specialty’s
approach to targeting the dysregulated immune system
in sepsis is key.
Recently, Antonakos et al. [6] replicated the often re-
ported finding that persistent impaired ex vivo cytokine
production of monocytes and lymphocytes stimulated
with either lipopolysaccharide (LPS) or Pam3 seen in
sepsis patients differs by survival status [4, 7]. LPS is a
conserved motif on Gram-negative bacteria. Pam3 is a
Toll-like receptor agonist.
The causal reasoning here and in similar studies is
that impaired cytokine production is a therapeutically
modifiable surrogate endpoint that can improve out-
comes in sepsis. This reasoning has not helped so far in
bringing new therapies to routine clinical use [5]. In this
editorial, I suggest that enhanced translation and smarter
interpretation of the sepsis immunology knowledge base
should derive extreme immune phenotypes, clarify bio-
markers’ purpose, identify surrogates in the causal path-
way of clinical outcomes, and define treatable traits
within sepsis cohorts (Table 1).
Extreme immune phenotypes in sepsis
The complex immune system alterations seen in sepsis
separate into two patterns, primarily based on mecha-
nisms contributing to late deaths [4, 7, 8]. In both these
host response patterns, pro-inflammatory, anti-
inflammatory, and immunosuppression responses are
activated at onset of sepsis and early deaths occur be-
cause of excessive innate immune system-driven in-
flammation. Recovery in both patterns is characterised
by resolution of inflammation and recovery of immune
cell paresis. However, late deaths occur either due to
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shankar-Hari Critical Care  (2017) 21:125 
DOI 10.1186/s13054-017-1715-0
progressive immune cell paresis resulting in secondary
infections or due to intractable inflammation-induced
organ injury or a combination of immunosuppression
and persistent inflammation [4, 7, 8]. These patterns
imply that there are at least two extreme immune pheno-
types within sepsis cohorts. For example, Davenport et al.
[9] identified two sepsis immune phenotypes in critically
ill adults with sepsis using whole leukocyte transcripto-
mics. About 40% of patients had an immunosuppressed
phenotype with impaired antigen processing ability sug-
gested by endotoxin tolerance and T-cell exhaustion. This
subgroup had a significantly higher mortality. However,
are we to infer that the remainder of the cohort had no
immunomodulation potential? Of note, much higher
validation cohort mortality in this study exemplifies
outcome heterogeneity in sepsis.
Biomarkers to stratify patients for interventions
and treatable traits
It is imperative to clarify the ability of numerous bio-
markers reported in sepsis literature [10] to either diagnose,
predict, prognosticate, and/or act as surrogate outcomes
[11]. For example, in the trial by Meisel and colleagues [12]
using granulocyte-monocyte colony stimulating factor
(GM-CSF), HLD-DR is positioned as a diagnostic bio-
marker for immunosuppression and as a surrogate out-
come for intervention, with a tenuous link to reported
clinical outcomes. The clinical outcomes that improved
were duration of mechanical ventilation and hospital stay
[12]. Interestingly 15% of patients in the control arm spon-
taneously restored their HLA-DR expression, which implies
that HLA-DR also identifies placebo responders. Promising
interventions in sepsis include interleukin-7, programmed
cell death pathway specific antibodies, interferon-γ, and
GM-CSF [4]. These therapies will need different biomarkers
for stratification, response prediction, and to work as surro-
gate outcomes. This also highlights the need to match
intervention with treatable traits to accomplish precision
medicine [3].
Surrogates in the causal pathway of clinical
end-points
Causal models represent a directional link between vari-
ables and their associated probabilities for a given set of
clinical circumstances. Therefore, it is important that
when trials report surrogate outcome(s), similar infer-
ences should be possible about likely clinical outcome(s).
Let us consider nosocomial infection as an example to
discuss this issue. Nosocomial infection is a difficult out-
come to define, its risk varies with time, and it competes
with mortality for event rate as it is associated with
greater illness severity, more inflammation, and greater
activation of endothelial markers [13]. The attributable
mortality when compared to non-sepsis controls is not
significantly higher [14]. Thus, the surrogate outcome
should ideally mirror these relationships observed with
clinical outcomes and should have a causal link.
In summary, our understanding of intervention-matched
extreme immune phenotypes and outcomes in sepsis trials
is not sophisticated enough to yield positive results. Whilst
a moratorium on trials is unreasonable, a consensus to-
wards study designs using fundamental principles of
population epidemiology and biological response character-
isation for immunomodulation trials is not.
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Table 1 Definitions of terminology
Terminology Definition
Extreme phenotypes Subpopulations defined by extremes of clinical features and outcomes
Biomarker Characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes,
or pharmacologic responses to a therapeutic intervention
Clinical outcome Characteristic that reflects how a patient feels, functions, or survives
Surrogate outcome Substitute for clinical endpoints (or outcome) and expected to predict clinical benefit or harm based on epidemiologic,
therapeutic, pathophysiologic, or other scientific evidence
Precision medicine Refers to an approach for disease treatment and prevention that considers individual variability in genes, environment, and
lifestyle
Heterogeneity The differences in the risk of developing sepsis, risk of suffering sepsis-related outcomes, and in treatment response
Treatable traits Selecting a patient population with a well-defined treatment response characteristic
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